National Health Investors reported second quarter 2026 results, with diluted earnings per share of $1.15 versus $0.79 a year earlier, helped by $22.0 million of property disposition gains. Normalized FFO per diluted share fell 2.5% to $1.19 for the quarter, though the company also raised its quarterly dividend to $0.94 from $0.92 and issued 2026 full-year NAREIT FFO guidance of $4.74 to $4.79 per diluted share.
Diluted EPS of $1.15 for Q2 2026 vs. $0.79 in Q2 2025; six-month diluted EPS of $1.97 vs. $1.53
Normalized FFO per diluted share of $1.19 for Q2 2026 vs. $1.22 in Q2 2025; six-month figure rose 2.1% to $2.42
Quarterly dividend increased to $0.94 per share from $0.92, payable November 6, 2026
NHC portfolio sale closed July 1, 2026 for $560.0 million in cash consideration
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From National Health Investors, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$80.06M
+47.1%
$3.02
-3.5%
177.6%
FY2024
$54.42M
+11.5%
$3.13
+0.0%
253.6%
FY2023
$48.81M
+36.4%
$3.13
+111.5%
277.9%
FY2022
$35.80M
—
$1.48
-39.3%
185.5%
FY2021
$0
—
$2.44
-41.1%
—
Frequently asked questions
When is National Health Investors's next earnings date?
National Health Investors (NHI) is scheduled to report on Monday, November 09, 2026 after the market closes. Analysts expect EPS of $1.17.
What did National Health Investors earn last quarter?
For the quarter ended Jun 2026, National Health Investors reported diluted EPS of $1.15 (+45.6% year over year) on revenue of $44.78M (+215.0%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.